Bellicum Pharmaceuticals, Inc.(BLCM)

Description: Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

---

Keywords: Medicine Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Prostate Cancer Cell Therapy Vaccination Immunotherapies Melanoma Transplantation Virotherapy Cancer Vaccine Hematopoietic Stem Cell Hematological Cancers Chimeric Antigen Receptor Resistant Prostate Cancer Dendritic Cell Treatment Of Hematological Cancers Metastatic Castrate Resistant Prostate Cancer Treatment Of Metastatic Castrate Resistant Prostate Cancer Treatment Of Various Forms Of Cancer

---

Home Page: www.bellicum.com

BLCM Technical Analysis

3730 Kirby Drive
Houston, TX 77098
United States
Phone: 281 454 3424

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)